doi: 10.5732/cjc.013.10218

Molecular biology of high-grade gliomas: what should the clinician know?

Silvia Hofer, Elisabeth Rushing, Matthias Preusser, Christine Marosi

Department of Medical Oncology, University Hospital Zürich, Zürich, Switzerland;

[Abstract] The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor (EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice.

Chinese Journal of Cancer 2014, Volume: 33, Issue 1, Page: 4-7

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

Cite this article

Silvia Hofer, Elisabeth Rushing, Matthias Preusser, Christine Marosi. Molecular biology of high-grade gliomas: what should the clinician know?. Chin J Cancer. 2014, 33(1):4-7. doi:10.5732/cjc.013.10218


Export citations

EndNote